At the 24th Congress of the European Hematology Association (EHA), Wojciech Jurczak from Jagiellonian University, Krakow, PL, discusses first-line therapy in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Dr. Jurczak draws attention to two studies, that are both changing clinical practice. The first study is GALLIUM for FL, which provided longer progression-free survival (PFS) data. He emphasizes that the more mature the data, the better it is. Dr. Jurczak discusses the first-ever randomized trial in CLL first-line therapy, carried out on 309 patients, where the new BTK inhibitor used provided better PFS and toxicity data.